Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
(NYSE: PFE) brought in enormous levels of revenue over the past couple of years thanks to its coronavirus vaccine and treatment. The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. But the next few years may not be as easy for the big pharma player.
Coronavirus products face a significant drop in demand as we head toward a post-pandemic world. And some of Pfizer's best-selling drugs, including Eliquis and Ibrance, face losses of exclusivity. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?
Before we get to the patent problem, let's talk about the COVID-19 situation. Last year, Pfizer generated more than $55 billion in revenue, combined, for its vaccine Comirnaty and treatment Paxlovid. But the market is shifting; demand is on the decline.
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 28.42 € bedeuten.
